Cymabay Therapeutics, Inc.

Ascendis Pharma Bone Diseases A/s

Metabolex, Inc.

Diatex, Inc.

David Brian Karpf

Charles A McWherter

Brian K Roberts

Robert Louis Martin

Xueyan Wang

Yun-Jung Choi

Kennett Sprogøe

Lars Holten-Andersen

Thomas Wegge

Joachim Zettler

Guillaume Maitro

Mathias Krusch

Felix Cleemann

Douglas Alan Lorenz

Rodney James Ketner

Ronald M Krauss

Francine M Gregoire

Martin E Sanders

Lars Holten-andersen

Kennett SprogØe

Claus Strange

Charles A Mcwherter

Brian Roberts

The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.

Incremental dose finding in controlled-release PTH compounds

The invention provides a method of treating or controlling hypoparathyroidism in a human patient by administering to the human patient a pharmaceutical composition comprising a controlled-release PTH compound or a pharmaceutically acceptable salt thereof. The controlled-release PTH compound comprises a PTH moiety reversibly conjugated to a branched polyethylene glycol carrier. The composition is administered by subcutaneous injection no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered by subcutaneous injection at the same dosing frequency required to maintain a serum albumin-adjusted calcium level in serum of above 8.5 mg/dL over a 24 hour period.

Controlled-release PTH compound

The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.

PTH compounds with low peak-to-trough ratios

The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

Dosage regimen for a controlled-release PTH compound

Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Treatment of NAFLD and NASH

The present invention provides methods for increasing LDL particle size.

Methods of reducing small, dense LDL particles

Treatment for NAFLD and NASH

This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.

Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Growing community of inventors

Mountain View, CA, United States of America

David Brian Karpf